AJTMH Tropical Medicine and Hygiene News
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am. J. Trop. Med. Hyg., 59(2), 1998, pp. 307-311
Copyright © 1998 by The American Society of Tropical Medicine and Hygiene

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Karanja, D.
Right arrow Articles by Secor, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Karanja, D.
Right arrow Articles by Secor, W.
Related Collections
Right arrow Schistosomiasis
Right arrow AIDS
American Journal of Tropical Medicine and Hygiene, Vol 59, Issue 2, 307-311
Copyright © 1998 by American Society of Tropical Medicine and Hygiene

Research Articles


Studies on schistosomiasis in western Kenya: II. Efficacy of praziquantel for treatment of schistosomiasis in persons coinfected with human immunodeficiency virus-1

DM Karanja, AE Boyer, M Strand, DG Colley, BL Nahlen, JH Ouma, and WE Secor

Praziquantel is the drug of choice for schistosomiasis chemotherapy. Although the exact mechanism of how praziquantel kills schistosomes remains poorly understood, the immune response of the host is an important factor in drug efficacy. It is thus possible that disease states of humans that lead to immunodeficiencies, such as infection with human immunodeficiency virus-1 (HIV-1), may render praziquantel less effective in treating schistosomiasis. To test this hypothesis, persons with high levels of Schistosoma mansoni infection who were or were not also infected with HIV-1 were treated with a standard regimen of praziquantel and monitored by quantitative fecal examination and plasma circulating cathodic antigen. Both groups responded to praziquantel therapy equally and individuals with low percentages (< 20%) of CD4+ T cells did not differ from individuals with higher CD4 cell percentages. These data demonstrate that persons with HIV-1 infection can be treated effectively for schistosomiasis with praziquantel.


This article has been cited by other articles:


Home page
 Arch DermatolHome page
P. Gholam, F. Autschbach, and W. Hartschuh
Schistosomiasis in an HIV-Positive Patient Presenting as an Anal Fissure and Giant Anal Polyp
Arch Dermatol, July 1, 2008; 144(7): 950 - 952.
[Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
V. MWANAKASALE, P. VOUNATSOU, T. Y. SUKWA, M. ZIBA, A. ERNEST, and M. TANNER
INTERACTIONS BETWEEN SCHISTOSOMA HAEMATOBIUM AND HUMAN IMMUNODEFICIENCY VIRUS TYPE 1: THE EFFECTS OF COINFECTION ON TREATMENT OUTCOMES IN RURAL ZAMBIA
Am J Trop Med Hyg, October 1, 2003; 69(4): 420 - 428.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
J. Utzinger, J. Keiser, X. Shuhua, M. Tanner, and B. H. Singer
Combination Chemotherapy of Schistosomiasis in Laboratory Studies and Clinical Trials
Antimicrob. Agents Chemother., May 1, 2003; 47(5): 1487 - 1495.
[Full Text] [PDF]

Home page
 NEJMHome page
A. G.P. Ross, P. B. Bartley, A. C. Sleigh, G. R. Olds, Y. Li, G. M. Williams, and D. P. McManus
Schistosomiasis
N. Engl. J. Med., April 18, 2002; 346(16): 1212 - 1220.
[Full Text] [PDF]

Home page
 Infect. Immun.Home page
A. S. MacDonald, M. I. Araujo, and E. J. Pearce
Immunology of Parasitic Helminth Infections
Infect. Immun., February 1, 2002; 70(2): 427 - 433.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1998 by the American Society of Tropical Medicine and Hygiene.